An early stage venture firm based in New York is investing from its third fund, which closed in 2013. The firm looks to invest in the Healthcare IT sector, and the initial investment size can range from $250k to $10million. The firm typically invests in companies at Seed and Series A stages.

The firm will consider companies across the US, and is currently looking for new opportunities in the Healthcare IT sectors. The firm will not consider devices or biotech companies. In the Healthcare IT sector, the firm is most interested in companies that do not need FDA approvals and focus on data, analytics, Internet, vertical applications and solutions. Historically, the firm was active in companies developing analytical platform, bioinformatics and software used in the pharmaceutical supply chain.

The firm primarily invests in pre-revenue companies, and prefers to invest in companies with a strong management team and significant growth potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global healthcare investment firm, headquartered in New York, is investing from an evergreen Life Sciences investment fund.

Typical allocations are up to $5M in early stage projects and $10-15M in late stage projects. With follow-on allocations, the total investment can reach up to $30M per company. The firm takes a mid- to long-term investment approach. The firm leverages flexible capital structures and can invest in both private and public companies. The firm often syndicates with major US venture capital firms, but it can also lead a financing round. The firm is currently seeking new opportunities with 80% focus on US and Canada and 20% on Western Europe.

The firm puts 70% focus on therapeutics and 30% on medical devices. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor interest in early-stage breakthrough science with strong management teams. In medical devices, the firm seeks to provide growth funding in de-risked medical devices and diagnostics in final approval steps, launch and international marketing efforts. The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric.

The firm focuses on five key disease areas: oncology, cardiovascular, anti-infectives, CNS/pain, and women’s health. In oncology, the firm seeks therapies with novel mechanisms of action and delivery, human data and signs of efficacy, and it also considers new generation diagnostics technologies. In cardiovascular diseases, the firm seeks life-saving therapies and technologies with strong human data. In anti-infectives the firm is considering pre-clinical assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which help women give birth to healthy children.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Taipei, Taiwan, solely invests in early stage medical technology ventures. The firm currently manages a fund which was raised in 2012 and closed at USD 100 million. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A strategic investment fund formed by a South America-based pharma company is seeking to invest in biotech companies.  For early-stage opportunities the fund typically makes equity investments and may syndicate with other investors, whereas for clinical-stage opportunities the fund is more likely to form strategic partnerships that involve rights to an asset.  The fund is open to considering therapeutic opportunities globally, but only if the company is pursuing the US market.

The fund invests in therapeutics; about 80% of the firm’s investments are in clinical-stage assets, with a preference for companies with some human proof-of-concept data; the remaining 20% of investments are made in preclinical opportunities.  Drug-device combinations will also be considered, but not diagnostics.  The firm will invest in both small and large molecules, and has a strong preference for investing in orphan drugs and other niche disease areas.  It is preferred that indications have validated clinical endpoints and can be studied using small trials.  Indications that require large clinical trials, including as cardiovascular diseases and primary care indications (such as influenza) will not be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A UK-based investment group has over £20 million under management. The group currently looks to invest in seed and early clinical stage companies in the life science space. The initial investment ranges from £50,000 to £300,000,but it will reserve capital for follow-on investments, and it can invest up to £1 million over a lifecycle. The group seeks to make 10-20 allocations over the next year. The group focuses on companies based in UK.

The group is currently looking for new opportunities in the Medical Devices, Diagnostics, Lab equipment and Healthcare IT sectors. The group will not invest in drug development companies. For medical devices, the group will consider all classes of devices but prefers devices with short regulatory pathways. The group is also interested companies that don’t require clinical trials. The group is generally opportunistic in terms of indication.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices in California and Hong Kong invests across a variety of sectors, including biotech and medical technology, and will be raising a second fund in 2015.  The firm typically invests $500,000-$1 million, and prefers to invest in seed or Series A rounds. The firm makes up to 12 allocations per year, and is interested in opportunities globally; companies developing products that can impact healthcare delivery in emerging markets such as China or India are of particular interest.

Within the life science field, the firm has a wide range of interests that include immuno-oncology, medical devices (particularly those involving sensors or remote technologies), software, wearables and consumer healthcare devices, and instrumentation/equipment for the healthcare or biotech sectors.  For therapeutic companies, Phase II opportunities are preferred but earlier opportunities may be considered; for medical devices, opportunities may be considered from development-stage through commercialization.  The firm does not invest in diagnostics.  The firm’s previous experience in the life science sector includes immuno-oncology drugs and 3D microscope technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An international, nonprofit global health organization with more than 30 offices around the world acts as a bridging agent between the public and commercial sectors for the development of health technologies for use in low-resource settings.

The organization provides funding to selected technology development projects in the form of non-dilutive research grants to help reduce business risks and encourage critical private-sector investment. Size of funding is variable according to individual project’s needs and funding agency’s specifications. Proposals are generally solicited through request for proposal (RFP) sessions that are open to public and private entities.

The organization managed a portfolio of projects focused on appropriate technology solutions for the health needs of people living in low-resource settings. Areas of expertise include diagnostic technologies (with a special focus on point-of-care diagnostics), digital health solutions, health technologies for women and children, reproductive health technologies, new solutions for contraception and STI/HIV prevention, vaccine and pharmaceutical technologies, and water and sanitation technologies. The organization is working on a wide arrange of communicable disease areas including HIV, neglected tropical diseases, malaria, and tuberculosis, as well as non-communicable diseases including cervical cancer, breast cancer, diabetes, and hypertension. The fund generally avoids funding basic research and large clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com